Study tests if starting stronger drugs earlier tames psoriatic arthritis
NCT ID NCT03739853
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed trial tested whether starting stronger medications early helps people with moderate to severe psoriatic arthritis more than the usual step-up approach. 192 adults were randomly assigned to standard care, early combination disease-modifying drugs, or early TNF inhibitors. The study measured disease activity using a composite score to see which strategy works best.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Methotrexate, Sulfasalazine, Leflunomide, Adalimumab
What this could lead to
If successful, this could show that starting stronger drugs earlier helps control psoriatic arthritis better than the usual step-up approach.
What could go wrong
This is a completed Phase 4 trial with 192 participants, so results are limited in size. More aggressive therapy may cause more side effects without clear benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIATIC ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Oxford University Hospitals NHS Trust
Oxford, Oxfordshire, OX3 7LD, United Kingdom